<DOC>
	<DOCNO>NCT01568047</DOCNO>
	<brief_summary>The purpose study investigate tolerability effect BIA 9-1067 steady-state levodopa pharmacokinetics Parkinson 's Disease ( PD ) patient treat levodopa/dopa-decarboxylase inhibitor .</brief_summary>
	<brief_title>Multicentre Study Four Parallel Groups Parkinson 's Disease ( PD ) Patients</brief_title>
	<detailed_description>Multicentre , double-blind , randomise , placebo-controlled study four parallel group PD patient treat standard-release levodopa/carbidopa 100/25 mg ( Sinemet® ) levodopa/benserazide 100/25 mg ( Madopar®/Restex® ) motor fluctuation ( `` wearing-off '' phenomenon )</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Benserazide , levodopa drug combination</mesh_term>
	<criteria>At screen ( admission baseline period ) : Male female nonchildbearing potential ( reason surgery postmenopausal ) ; Age ≥ 30 year ; A diagnosis PD accord UK PDS Brain Bank diagnostic criterion ( bradykinesia least one following : muscular rigidity , rest tremor postural instability ) ; Predictable sign endofdose deterioration despite `` optimal '' levodopa/carbidopa levodopa/benserazide therapy ; Modified Hoehn Yahr stage less 5 `` '' state ; mean duration `` '' state ≥ 1.5 h waking hour ( base historical information ) ; Results clinical laboratory test acceptable investigator ( clinically significant wellbeing patient purpose study ) ; Able willing give write informed consent . At randomisation ( completion baseline period ) : Been treat stable regimen 3 8 dos per day standardrelease levodopa/carbidopa 100/25 mg ( Sinemet® ) levodopa/benserazide 100/25 mg ( Madopar®/Restex® ) least 1 week prior randomisation ; Mean duration `` '' state ≥ 1.5 h waking hour ( average recording last 3 evaluable day patient 's diary ) ; Concomitant antiParkinsonian medication ( apomorphine , entacapone tolcapone ) stable dos least 4 week prior admission . At screen ( admission baseline period ) : Nonidiopathic parkinsonism ( atypical parkinsonism , symptomatic parkinsonism , Parkinsonplus syndrome ) ; Treated entacapone , tolcapone , neuroleptic , antidepressant ( except serotoninspecific reuptake inhibitor imipramines [ desipramine , imipramine , clomipramine amitriptyline ] ) , monoamine oxidase inhibitor ( except selegiline 10 mg/day oral formulation 1.25 mg/day buccal absorption formulation rasagiline 1 mg/day ) antiemetic ( except domperidone ) within 2 week prior admission ; Treated investigational product within 1 month prior admission ( within 5 halflives , whichever long ) ; A psychiatric medical condition might place him/her increase risk interfere assessment ; Known hypersensitivity ingredient investigational product ; A history abuse alcohol , drug medication within last 2 year ; A clinically relevant ECG abnormality ; A history current evidence heart disease , include limited myocardial infarction , angina , congestive heart failure cardiac arrhythmia ; Unstable concomitant disease treat change dos medication ; A history current evidence relevant disease context study , i.e. , respect safety patient ( e.g. , hepatic impairment ) relate study condition ; A test positive HIV1 HIV2 antibody , hepatitis B surface antigen ( HbsAg ) , hepatitis C antibody ( HCVAb ) ; Donated blood receive blood blood product within 6 month prior admission ; Pregnant , breastfeed childbearing potential ; Other condition circumstance , opinion investigator , may compromise patient 's ability comply study protocol . At randomisation ( completion baseline period ) : Treated levodopa/DDCI 10:1 ratio controlledrelease formulation baseline period ; Treated apomorphine baseline period ; A clinically relevant ECG abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>BIA 9-1067</keyword>
</DOC>